Search

everythinglearnresearchcommunity

for

Search:↓

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

CEC levels may be a useful marker for predicting prostate cancer progression.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.

Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.

Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.

A vaccine may prevent benign prostatic hyperplasia (BPH).

Finasteride reduces prostate size and serum levels, helping manage benign prostatic hyperplasia, without affecting prostate cancer detection. Regular monitoring is needed for users.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Men with enlarged prostates often have more severe baldness.

Women with congenital adrenal hyperplasia showed no prostatic growth.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Castration is preferred for non-breeding male dogs with BPH, but other treatments are available with specific pros and cons.

Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.

Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.

Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

Family doctors can manage older men with urinary symptoms using exams, tests, and medications.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.